PDCD1 and neoplasm: The safety andactivity of the combination of pembrolizumab and T-VEC, which increases tumor-derivedantigen expression and T cell infiltrate and may act in synergy with PD-1 blockade,was explored in a phase Ib study: the combination was well tolerated, with no DLTsbeing observed and no patients discontinuing treatment due to treatment-relatedadverse events, and active, with an overall response rate of 56% [85–86].